Table 1.
Baseline characteristics of enrolled participants.
| Characteristics (N = 575) | N (%)/mean ± s.d |
|---|---|
| Age | 59.63 ± 10.13 |
| Sex | |
| Male | 362 (63.0%) |
| Female | 213 (37.0%) |
| Tumor type | |
| Gastric cancer | 115 (20.0%) |
| Colorectal cancer | 310 (53.9%) |
| Hepatocellular carcinoma | 60 (10.4%) |
| Esophageal cancer | 30 (5.2%) |
| Pancreatic cancer | 36 (6.3%) |
| Biliary malignant tumor | 24 (4.2%) |
| Stage | |
| I | 41 (7.1%) |
| II | 134 (23.3%) |
| III | 181 (31.5%) |
| IV | 219 (38.1%) |
| Smoke history (n = 471a) | |
| No | 250 |
| Yes/ever | 221 |
| Alcohol history (n = 471a) | |
| No | 341 |
| Yes/ever | 130 |
| Nutrition support (n = 471a) | |
| No | 285 |
| Yes/ever | 186 |
| BMI | 22.55 ± 3.35 |
| KPS | 88.30 ± 11.30 |
| Nutritional statusb | |
| Well-nourished | 148 (25.74%) |
| Moderate malnutrition | 260 (45.22%) |
| Severe malnutrition | 167 (29.04%) |
| HRQoL | 68.70 ± 20.15 |
| Treatment after admission | |
| Surgical resection | 350 (60.87%) |
| Chemotherapy | 497 (86.43%) |
| Radiotherapy | 36 (6.26%) |
| Targeted therapy | 50 (8.70%) |
| Immunotherapy | 17 (2.96%) |
BMI, body mass index; KPS, Karnofsky performance status; PG-SGA, the patient-generated subjective global assessment; HRQoL, health-related quality of life.
aDue to missing or low-quality data, some participants lack information on smoke history, alcohol history and nutritional support. The sample size that can be used after quality control is 471, accounting for 82% of the total sample size.
bNutritional status was classified according to the PG-SGA scores: Well-nourished (PG-SGA scores ≤ 2 points); Moderate malnutrition (3 ≤ PG-SGA scores ≤ 8 points); Severe malnutrition (PG-SGA scores ≥ 9 points).